Pharmaceutical Technology on MSN9h
AstraZeneca director says AI must be a “thought partner” in drug discoveryAstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.
Investor's Business Daily on MSN6h
AstraZeneca Stock Scores RS Rating UpgradeAstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...
Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...
The latest trading session saw Astrazeneca (AZN) ending at $77.47, denoting a -0.63% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.78%.
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...
The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback